Abstract: This disclosure provides a method of safely and rapidly initiating or escalating oral sotalol therapy by administering an intravenous dosage of sotalol followed by oral sotalol twice daily.
Type:
Grant
Filed:
November 24, 2019
Date of Patent:
July 11, 2023
Assignee:
AltaThera Pharmaceuticals, LLC
Inventors:
John Somberg, Brandon Ira Kashfian, Janos Molnar
Abstract: The disclosure relates to a method which includes i) prompting input of: a creatinine clearance (CrCl) of a subject; whether the subject is being initiated or escalated on sotalol hydrochloride; an amount of an oral target dosage of sotalol hydrochloride for the subject; and optionally a projected start time for sotalol hydrochloride infusion; and ii) executing computer executable instructions to derive from a set of rules a sotalol hydrochloride dosing protocol for the subject based on the inputs. The disclosure also relates to systems and medical devices configured to perform one or more steps of the method, as well as a non-transitory computer-readable storage medium comprising computer-executable instructions or software stored thereon capable of performing one or more steps of the method.
Abstract: The present invention provides a novel method of converting AF and monitoring normal sinus rhythm using an initial IV dose of sotalol followed by oral sotalol maintenance therapy. This method provides a method of acute assessment of QTc prolongation to determine the safety of chronic oral sotalol therapy and reduces the hospitalization stay required for conversion and sotalol initiation.
Abstract: This disclosure provides method of safely and efficaciously treating or preventing atrial fibrillation, atrial flutter, or a combination thereof via rapid intravenous introduction of sotalol hydrochloride to a subject in need thereof.
Type:
Grant
Filed:
August 14, 2018
Date of Patent:
December 24, 2019
Assignee:
AltaThera Pharmaceuticals, LLC
Inventors:
John Charin Somberg, Brandon Ira Kashfian, Janos Molnar